Hydergine ® - Weil, Claude

. .

Sommaire:
I. Introduction and Background Information.- II. Basic Pharmacologic Properties: Peripheral Effects on Neurotransmission.- 1. Actions at Adrenoceptors.- a) Antagonistic Effects at Postjunctional Alpha-Adrenoceptors.- b) Effects on Noradrenaline Release.- c) Depletion and Reuptake of Noradrenaline from Tissues.- 2. Actions at Dopamine Receptors.- 3. Actions at Serotonin (5-HT) Receptors.- a) Agonist Effects at 5-HT Receptors.- b) Antagonistic Effects at 5-HT Receptors.- 4. Miscellaneous and Unspecific Effects.- III. Basic Pharmacologic Properties: Central Effects.- 1. Effects on Neurotransmission.- a) Actions at Adrenoceptors.- b) Actions at Dopamine Receptors.- c) Actions at Serotonin (5-HT) Receptors.- d) Effects on Cholinergic Neurotransmission.- e) Interactions with Neuropeptides.- 2. Effects on Brain Enzymes and Metabolism.- a) Adenosine Triphosphatase (ATPase) and Adenosine Triphosphate (ATP).- b) Adenyl Cyclase.- c) Cyclic-AMP Phosphodiesterase (PEase).- d) Metabolism: Oxygen Utilization, Glucose Utilization and Metabolism, Sundry.- 3. Effects on Cerebral Blood Flow.- 4. Other Effects.- a) Behavioral Excitation and Depression.- b) Interaction with Centrally Depressant Drugs.- c) Anticonvulsant Effects.- d) Effects on Body Temperature.- e) Emetic Effects.- f) Effects on the Electroencephalogram (EEG).- g) Effects on Learning, Memory, and Various Types of Behavior.- h) Behavioral Response to Repeated Administration.- 5. Conclusions.- IV. Effects of Co-Dergocrine on the Cardiovascular System.- V. Effects of Co-Dergocrine on Other Organs and Cells.- 1. Effects on the Uterus.- 2. Effects on the Kidney.- 3. Effects on Blood Platelets.- VI. The Clinical Pharmacology of Co-Dergocrine in Age-Related Cerebral Insufficiency.- 1. Cerebral Blood Flow (CBF).- 2. Clinical Rating Scales.- 3. Psychometric Tests.- 4. Electroencephalography.- VII. Co-Dergocrine in Various Cardiovascular and Cerebral Indications.- 1. Arterial Hypertension.- 2. Shock.- 3. Stroke.- 4. Inner-Ear Disorders.- 5. Tardive Dyskinesia.- VIII. Biopharmaceutical Aspects.- IX. Toxicologic Considerations.- References.